Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Dominique Mignard"'
Autor:
Thierry Poynard, Laurent Hannoun, Julien Taieb, David Malka, Mohamed Hebbar, Valérie Boige, Dominique Mignard, Emmanuelle Magherini, Thierry Debaere, Michel Ducreux
Publikováno v:
European Journal of Cancer. 42:456-459
This study assessed the clinical activity and safety of irinotecan (CPT-11) in patients with advanced hepatocellular carcinoma (HCC) using dose adjustment according to baseline serum bilirubin level. Patients with advanced HCC received CPT-11 at a do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9b0b5bdfc1367c541f8fbec32d59019
https://doi.org/10.1016/j.ejca.2005.09.034
https://doi.org/10.1016/j.ejca.2005.09.034
Autor:
Harry Bleiberg, Philippe Rougier, Gilles Freyer, Patrice Herait, Lucile Awad, Dominique Mignard, Véronique Trillet-Lenoir, J.P. Droz, Stéphane Culine, Michel Marty, Roland Bugat
Publikováno v:
British Journal of Cancer
Our purpose was to determine, in patients with metastatic colorectal carcinoma treated with irinotecan single-agent after 5-FU failure, the most significant predictive parameters for tumour response, progression-free survival and toxicity. Between Oc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68e19432aa655870ef372cdf554820ed
https://doi.org/10.1054/bjoc.2000.1303
https://doi.org/10.1054/bjoc.2000.1303
Autor:
Pierre Fumoleau, Yvan Krakowski, J. L. Misset, Philippe Vennin, Jacques Chauvergne, M.A. Lentz, Catherine Lhommé, B. Chevallier, Pierre Fargeot, Paul Rebattu, Anne Matthieu-Boue, Martine Van Glabbeke, H. Roche, Véronique Diéras, Dominique Mignard
Publikováno v:
Journal of Clinical Oncology. 17:3136-3142
PURPOSE: To determine the efficacy and tolerability of irinotecan (CPT-11) in advanced or recurrent cervical carcinoma. PATIENTS AND METHODS: Eligible patients had histologically confirmed, inoperable, progressive, metastatic or recurrent squamous ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64a813af073975a5a0393efb40629c3c
https://doi.org/10.1200/jco.1999.17.10.3136
https://doi.org/10.1200/jco.1999.17.10.3136
Autor:
M Mahjoubi, Marc Bonnay, G. Bastian, C. Cote, R. Hagipantelli, Dominique Mignard, Esteban Cvitkovic, Patrice Herait, Gilles Vassal, J. L. Misset, F. Saliba
Publikováno v:
Journal of Clinical Oncology. 16:2745-2751
PURPOSE Irinotecan (CPT-11), a camptothecin derivative, has shown efficacy against colorectal cancer. Delayed-onset diarrhea is its main limiting toxicity. The aim of this study was to determine the pathophysiology of CPT-11-induced delayed-onset dia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::012d2c6f4ab1ee39c21886d75711cba1
https://doi.org/10.1200/jco.1998.16.8.2745
https://doi.org/10.1200/jco.1998.16.8.2745
Autor:
F Pein, François Doz, Karima Imadalou, Gilles Vassal, Evelyne Sicard, Alexandre Santos, C. Germa, Didier Frappaz, John O'Quigley, Dominique Mignard, Marie-Laure Risse
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 21(20)
Purpose: A phase I study was performed to determine the maximum-tolerated dose (MTD) and safety profile of irinotecan (CPT-11) administered as a single intravenous infusion every 3 weeks in children with recurrent or refractory solid tumors. Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb9990fac081f83d2d3b20a799e6b470
https://pubmed.ncbi.nlm.nih.gov/14551303
https://pubmed.ncbi.nlm.nih.gov/14551303
Autor:
Erick Gamelin, Sylvie Negrier, Olivier Rixe, Jean-Yves Pierga, Mireille Mousseau, Yves Becouarn, Dominique Mignard, Claude Krisch, Bruno Coudert, Jean-Luc Raoul, C. Germa, Mohamed Bekradda, Jocelyne Provencal
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(22)
PURPOSE: To assess antitumor activity and safety of two regimens in advanced colorectal cancer (CRC) patients with proven fluorouracil (5-FU) resistance in a randomized phase II study: 5-FU/folinic acid (FA) combined with alternating irinotecan (also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b36ccce9ecaca26e522df59ee3786134
https://pubmed.ncbi.nlm.nih.gov/11709562
https://pubmed.ncbi.nlm.nih.gov/11709562
Autor:
Patrick Dufour, Mireille Mousseau, Dominique Mignard, Jean-Yves Douillard, J. L. Wendling, F. Burki, Philippe Rougier, Michel Marty, Antoine Adenis, Marc Ychou
Publikováno v:
American journal of clinical oncology. 23(2)
Delayed diarrhea is the main toxicity of irinotecan at the currently recommended dose of 350 mg/m 2 30-minute intravenous infusion, once every 3 weeks. This phase II, multicenter, open-label, randomized study was primarily designed to evaluate the ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0e440b62f3ab2f6c1b8b0b9f1019bba
https://pubmed.ncbi.nlm.nih.gov/10776974
https://pubmed.ncbi.nlm.nih.gov/10776974